United Therapeutics authorizes another $2 billion of share repurchases

United Therapeutics ($UTHR) approved an additional share-repurchase program of up to $2 billion, running for one year through October 21, 2027. The company may use accelerated repurchase agreements, open-market transactions, privately negotiated purchases or other methods. The authorization expands the amount of capital potentially returned to shareholders.

The new allocation is separate from an accelerated repurchase agreement initiated under an earlier authorization, which is expected to conclude in the fourth quarter, subject to its terms. Purchases under the new program will depend on market conditions, financial considerations and management decisions. The company is not required to buy a minimum number of shares and may suspend the program. The headline amount is therefore an authorization ceiling, not a completed $2 billion distribution.

Sources:

• Business Wire
• United Therapeutics — issuer repurchase announcement